Spyre Therapeutics
SYRE
129 hedge funds and large institutions have $1B invested in Spyre Therapeutics in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 53 increasing their positions, 35 reducing their positions, and 21 closing their positions.
51% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 35
1.07% more ownership
Funds ownership: 102% → 103.07% (+1.1%)
10% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 21
2% less funds holding
Funds holding: 131 → 129 (-2)
18% less call options, than puts
Call options by funds: $827K | Put options by funds: $1.01M
28% less capital invested
Capital invested by funds: $1.39B → $1B (-$390M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$49.8M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$42.7M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$12.5M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$8.74M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19.7M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$11.6M |
| 3 |
Goldman Sachs
New York
|
-$11.5M |
| 4 |
BCM
Boxer Capital Management
San Diego,
California
|
-$10.9M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$8.64M |
SYRE Hedge Fund Activity: Q1 2025 in Review
129 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2025, worth a combined $1B — down 28% from $1.39B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of SYRE and 19 opened new positions — a net loss of 2 holders — while 35 trimmed existing stakes and 53 added.
The largest buyer was Capital International Investors, opening a new position worth an estimated $49.8M. The largest seller was Citadel Advisors, cutting an estimated $19.7M.
- 129 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2025, down from 131 in Q4 2024.
- Funds reported $1B of Spyre Therapeutics stock for Q1 2025, down 28% quarter-over-quarter.
- 19 funds opened new Spyre Therapeutics positions in Q1 2025 and 21 closed out, a net change of -2 holders.
- The largest Spyre Therapeutics buyer in Q1 2025 was Capital International Investors, an estimated $49.8M added.
- The largest Spyre Therapeutics seller in Q1 2025 was Citadel Advisors, an estimated $19.7M sold.
Based on aggregated 13F filings for Q1 2025.